ARGENX SE's ticker is ARGX and the CUSIP is 04016X101. A total of 290 filers reported holding ARGENX SE in Q2 2023. The put-call ratio across all filers is 1.54 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,223,667 | +31.3% | 2,489 | +4.1% | 0.00% | – |
| Q2 2023 | $932,234 | -98.1% | 2,392 | -98.2% | 0.00% | -100.0% |
| Q1 2023 | $48,806,780 | +2340.1% | 132,036 | +2400.7% | 0.00% | – |
| Q4 2022 | $2,000,222 | +87.6% | 5,280 | +75.0% | 0.00% | – |
| Q3 2022 | $1,066,000 | +5.9% | 3,018 | +13.6% | 0.00% | – |
| Q2 2022 | $1,007,000 | +73.0% | 2,657 | +43.9% | 0.00% | – |
| Q1 2022 | $582,000 | -13.9% | 1,847 | -4.3% | 0.00% | – |
| Q4 2021 | $676,000 | +21.4% | 1,929 | +4.2% | 0.00% | – |
| Q3 2021 | $557,000 | -96.4% | 1,851 | -96.4% | 0.00% | -100.0% |
| Q2 2021 | $15,314,000 | -0.4% | 50,865 | -8.9% | 0.00% | 0.0% |
| Q1 2021 | $15,376,000 | +1848.8% | 55,833 | +1990.3% | 0.00% | – |
| Q4 2020 | $789,000 | -89.6% | 2,671 | -90.7% | 0.00% | -100.0% |
| Q3 2020 | $7,575,000 | +2004.2% | 28,856 | +1704.6% | 0.00% | – |
| Q2 2020 | $360,000 | -70.6% | 1,599 | -81.5% | 0.00% | – |
| Q2 2019 | $1,226,000 | – | 8,656 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 273,343 | $106,529,967 | 17.42% |
| Kynam Capital Management, LP | 184,300 | $71,827,239 | 9.88% |
| Ikarian Capital, LLC | 132,100 | $51,483,333 | 8.20% |
| Avoro Capital Advisors LLC | 1,263,500 | $492,423,855 | 6.68% |
| Artia Global Partners LP | 46,438 | $18,098,282 | 6.24% |
| DCF Advisers, LLC | 25,700 | $10,016,061 | 5.29% |
| Bellevue Group AG | 923,284 | $359,831,473 | 5.13% |
| Eagle Health Investments LP | 64,400 | $25,098,612 | 4.69% |
| Paradigm Biocapital Advisors LP | 150,000 | $58,459,500 | 4.52% |
| Paradigm Biocapital Advisors LP | 142,259 | $55,442,600 | 4.28% |